Plasma Fractionation Market Report Scope & Overview:

The plasma fractionation market size was valued at USD 38.50 billion in 2025E and is expected to reach USD 73.18 billion by 2033, growing at a CAGR of 8.36% over the forecast period of 2026-2033.

The global plasma fractionation market is growing at a strong rate as demand for plasma-derived therapies such as immunoglobulins, albumin, and coagulation factors is increasing. The nervous system disorders segment holds the largest market share, followed by musculoskeletal disorders, which can be attributed to the increasing prevalence of such disorders in the immune system and bleeding, along with the growing population and better diagnosis. In addition, market expansion is fostered by technological advancement in fractionation methods and the availability of an ever-increasing number of plasma collection centers.

Market Size and Forecast

• Market Size in 2025E: USD 38.50 Billion

• Market Size by 2033: USD 73.18 Billion

• CAGR: 8.36% from 2026 to 2033

• Base Year: 2025

• Forecast Period: 2026–2033

• Historical Data: 2022–2024

Plasma Fractionation Market Trends

• Rising prevalence of immunodeficiency, hemophilia, and chronic diseases is driving the plasma fractionation market.

• Growing demand for immunoglobulins, clotting factors, and albumin is boosting market growth.

• Expansion of blood collection centers and plasma donation programs is increasing raw material availability.

• Advancements in fractionation technologies and purification processes are enhancing safety and yield.

• Focus on regulatory compliance, quality standards, and pathogen reduction is shaping market trends.

• Increasing adoption of recombinant and plasma-derived therapies is widening application scope.

• Collaborations between biopharmaceutical companies, research institutions, and healthcare providers are accelerating innovation and commercialization.

The U.S. plasma fractionation market size was valued at USD 15.13 billion in 2025E and is expected to reach USD 28.02 billion by 2033, growing at a CAGR of 8.01% over the forecast period of 2026-2033.

The U.S. dominates the North American plasma fractionation market growth owing to its large network of plasma collection centers, strong manufacturing infrastructure, and presence of key industry players. Attractive regulatory environments and growing need for plasma-derived therapies further consolidate its leading role in the region.

Plasma Fractionation Market Growth Drivers:

• Increase Plasma Collection and Fractionation Plant is Driving the Market Growth

As plasma-derived therapies have gained popularity, there has been a growing demand for these plasma-derived therapies from the global market, and hence, major players in the market have directed their resources in terms of capital and developing associated infrastructure for the collection and fractionation of plasma. A range of organisations is both establishing new plasma donation centres and expanding the capacity of current fractionation plants to boost output, including CSL Behring, Takeda, Octapharma, and Grifols. As an example, Takeda needed to expand one of its largest fractionation houses to accommodate global demands, specifically in Los Angeles. 

Feb 2025: Octapharma unveils huge expansion plan at Vienna plasma fractionation plant. Costing 200million, the extension was finished in just 15 months and has boosted the production area by more than two-thirds and created a further 160 jobs. The enhanced facility now accommodates a 50% increase in production capability and provides packaging capability that is twice as fast, allowing the rapid worldwide distribution of plasma-derived therapeutics for immunology, hemophilia, and critical care.

• Technological Advancements in Fractionation Methods are Propelling the Market Growth

Plasma fractionation is a classic process that has received a face-lift, in which a number of innovative separation and purification technologies have become the norm. Chromatography, depth filtration, and novel viral inactivation techniques supplement traditional methods to achieve higher product yield, purity, and safety. They enable a more efficient isolation of high-value plasma proteins such as immunoglobulins, albumin, and clotting factors. Improved automation and closed processing systems also minimize contamination risks and production errors. 

In March 2025, Octapharma achieved an important milestone, as the only fractionator of the UK Plasma‑for‑Medicines programme with UK-sourced, non-paid plasma for the first time in nearly three decades. The program integrates automated plasmapheresis with available state-of-the-art viral inactivation and filtration measures at NHS Blood and Transplant centers. This does not account for the albumin, which is intended to be up to 80% self-sufficient by 2026, and the immunoglobulins up to 2031 (30−35%), which is consistent with a significant improvement in the safety and resilience of the supply chain.

Plasma Fractionation Market Restraints:

• Stringent Regulatory Requirements are Challenging the Market for Growth

Plasma-derived therapies are sensitive biological products with the risk of some blood-borne pathogen transmission. As a result, the regulators, e.g., FDA (U.S.), EMA (Europe), and PMDA (Japan), require the highest standards of safety, quality, and efficacy for the plasma fractionation process and final products. Rigorous compliance measures are necessary for manufacturers to prove compliance through clinical trials, virus inactivation validation, donor screening protocols, and batch traceability.Although these requirements are vital for ensuring patient safety, they can lengthen product development cycles, increase production costs, and require numerous audits or facility inspections. Complicating these issues are regulatory differences between regions that often make international approvals and distribution logistics more challenging to work through. 

Plasma Fractionation Market Segmentation

By Products, Immunoglobulins dominate the plasma fractionation market, Albumin is expected to grow fastest

The plasma fractionation market share was dominated by the immunoglobulins segment in 2025, with a 64.10%, due to the growing incidence of immunodeficiency disorders, autoimmune diseases, and neurological conditions that benefit from immunoglobulin therapy. These products are commonly utilized in different healthcare settings for the management of various disorders like primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), and other immune-mediated conditions. 

The albumin segment is estimated to grow at a faster rate throughout the forecast period due to growing applications of albumin in critical care, liver diseases, and during surgical procedures. Evolving healthcare access, due in part to improved cost of healthcare in developing countries, has driven some awareness of the place of albumin in fluid replacement therapy, treatment of shock, and recovery from burns. 

By Method, Chromatography leads the market, Centrifugation is expected to grow fastest

In 2025, the chromatography segment held the largest share of the plasma fractionation market with a 35.6% market share, as it can achieve higher purity and selectivity in the separation of plasma proteins compared to other methods. Several chromatographic techniques, including ion-exchange, affinity, and size-exclusion, can be applied to prepare plasma proteins selectively, such as immunoglobulins, albumin, and coagulation factors. 

The centrifugation segment is expected to be the fastest-growing segment in the forecast period, owing to the increasing application of centrifugation in early-stage plasma processing and smaller-scale or decentralized fractionation systems. Centrifugation provides an inexpensive and efficient method for the separation of plasma components based upon their density differentials and is therefore well suited for emerging market needs and new plasma collection centers.

By Application, Neurology dominates, Oncology is projected to grow fastest

The neurology segment dominated the plasma fractionation market in 2025 with a 29.8% market share due to the widespread application of immunoglobulins against neurological diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome, and multifocal motor neuropathy. These disorders often need prolonged immunoglobulin treatment, leading to a steady demand in the neurology segment.

Due to increasing research and clinical application of plasma derivative products in cancer care and supportive treatments, the oncology segment is projected to be the fastest growing throughout the forecast period. Albumin-based chemotherapies (nab-paclitaxel, etc) utilize plasma proteins (e.g., albumin) to serve as a drug carrier, improving delivery and effectiveness in the oncology setting. Immunoglobulins may also be used to control oncologic immune complications and infections. 

By End-Use, Hospitals & clinics dominate the market, Clinical research is expected to grow fastest

In 2025, the plasma fractionation market was dominated by the hospitals & clinics segment with a 54.11% market share, attributed to the intravenous administration of plasma-derived therapies in the acute and chronic care settings. These healthcare facilities are the first line of care for patients who need immunoglobulins for immunodeficiencies, albumin for critical care, and coagulation factors for bleeding disorders such as hemophilia. 

The clinical research segment is expected to witness the fastest growth during the forecast period due to the continuous research and development to increase the therapeutic indications for plasma-derived products. Rising investment in clinical trials for new indications, enhanced formulations, and combination therapies is boosting demand in this segment. Plasma proteins from blood are being investigated within novel indications by academic institutions, biotech firms, and pharmaceutical companies, such as oncology and rare genetic diseases. 

Plasma Fractionation Market Regional Analysis

North America Plasma Fractionation Market Insights

The plasma fractionation market share dominated North America with a 51.62% market share in 2025, driven by previously existing health infrastructure, awareness about plasma-derived therapies, and domination of key players such as CSL Behring, Grifols, and Takeda. There is a stable and large supply of source plasma in the region due to a well-established network of plasma collection centers, especially in the U.S.. Meanwhile, North America will continue to dominate the global market, which is further strengthened by its favorable reimbursement policies, early uptake of advanced fractionation technologies, and a larger patient pool suffering from immunological and bleeding disorders.

Asia Pacific Plasma Fractionation Market Insights

The plasma fractionation market is expanding at a significant rate in Asia Pacific due to growing investments in healthcare, rising diagnosis rates for rare and chronic diseases, and improving access to next-generation therapies. Rapid expansion of plasma collection and processing infrastructure in country markets (China, India, and Japan) is driven by supporting government initiatives and local manufacturing incentives The market in the region is witnessing strong growth due to the increasing awareness regarding plasma-derived products along with the increasing demand for immunoglobulins and albumin in the geriatric population.

Europe Plasma Fractionation Market Insights

The European plasma fractionation market trends are expanding due to the existing scale of countries' biopharmaceutical infrastructure, accommodating regulatory environment, and rising demand for plasma-derived therapies. There is an efficient delivery network of hospitals in the region, and rapid uptake of biologic treatments is highest for immunological, hematological, and neurological diseases. Furthermore, regional production capacity is being further bolstered by investments in plasma collection and processing, plus some R&D activity.

Middle East & Africa and Latin America Plasma Fractionation Market Insights

The global plasma fractionation market is witnessing modest growth in Latin America and MEA (Middle East & Africa), largely due to the gradual development of healthcare infrastructure and a higher level of awareness about the benefits of plasma-derived therapies. Although the plasma networks across the region are still relatively nascent, some countries have already opened up new centres, whilst also maximizing the potential for existing ones. Partnerships with global manufacturers and regulatory bodies aiming to harmonize plasma product approval processes are enabling this progressive scaling up.

Plasma Fractionation Market Competitive Landscape:

Octapharma AG

Octapharma, founded in 1983 and headquartered in Lachen, Switzerland, is a global biopharmaceutical company specializing in human protein therapies derived from plasma and recombinant technologies. The company focuses on producing plasma-derived medicinal products (PDMPs) for rare and chronic diseases, including hemophilia, immune deficiencies, and critical care treatments. Octapharma emphasizes innovation, patient safety, and sustainable plasma sourcing to enhance global access to life-saving therapies while supporting local healthcare systems and plasma supply chains.

• March 2025: NHS patients in the UK are receiving drugs made by Octapharma from UK-donated plasma for the first time in nearly 30 years, strengthening local plasma supply chains and reducing reliance on foreign plasma-derived medicines.

Takeda Pharmaceutical Company Limited

Takeda, founded in 1781 and headquartered in Tokyo, Japan, is a global biopharmaceutical leader with expertise in plasma-derived therapies, oncology, rare diseases, and gastroenterology. The company emphasizes innovative biologics, patient-centric care, and scalable manufacturing to meet growing global demand. Takeda invests heavily in production capacity, automation, and process optimization to support plasma fractionation and ensure the reliable supply of high-quality plasma-derived therapies to healthcare providers worldwide.

• June 2024: Takeda announced a major expansion of its plasma-derived therapies manufacturing capacity at its Los Angeles plant, the company’s largest plasma fractionation site, reinforcing its commitment to meet increasing global PDT demand.

CSL Behring

CSL Behring, headquartered in King of Prussia, Pennsylvania, USA, is a leading global biotechnology company specializing in plasma-derived therapies and recombinant proteins for rare and serious diseases. The company focuses on innovation, automation, and process efficiency to enhance plasma fractionation, treatment quality, and supply reliability. CSL Behring develops therapies for hemophilia, immune deficiencies, and critical care, combining global scale with advanced manufacturing technologies to meet the growing needs of patients worldwide.

• March 2023: CSL Behring inaugurated its "Phoenix" base fractionation plant in Marburg, Germany, following a five-year, USD 470 million investment, significantly increasing plasma processing capacity and incorporating automation to improve production of plasma-derived treatments.

Key Players

Some of the Plasma Fractionation Market Companies

• CSL Behring

• Grifols S.A

• Takeda Pharmaceutical Company Limited

• Octapharma AG

• Kedrion Biopharma Inc.

• Bio Products Laboratory (BPL)

• Sanquin

• LFB S.A.

• China Biologic Products Holdings Inc.

• Green Cross Corporation (GC Pharma)

• Syntegon

• Hualan Bio

• Intas Pharmaceuticals Ltd.

• Biotest AG

• Bio Products Laboratory Ltd. (BPL)

• Shanghai RAAS Blood Products Co., Ltd.

• Sanquin

• Kamada Ltd.

• Haemonetics Corporation

• Mitsubishi Tanabe Pharma Corporation